NSE filing, NSE: HSCL. Summary written from the filing by ALFA Finder's alert engine.
Himadri Speciality Chemical Ltd: key numbers
- Share price
- ₹530.55
- Market cap
- ₹26,770 Cr
- Revenue (annual)
- ₹4,661 Cr
- Net profit (annual)
- ₹751.3 Cr
- P/E (TTM)
- 31.3×Sector 34.1×
- Promoter holding
- 52.49%-0.01% QoQ
- FII holding
- 7.33%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Himadri Speciality Chemical Ltd
All →Himadri Speciality Chemical Other Announcement
Himadri Speciality Chemical's members approved an alteration of its Memorandum of Association and adoption of a new MOA under the Companies Act, 2013. The approval was by special resolution through postal ballot on October 27, 2026.
Himadri Speciality Chemical Annual General Meeting
Himadri Speciality Chemical announced postal ballot results approving a special resolution to alter and adopt a new Memorandum of Association. Remote e-voting concluded 27 October 2026 with the requisite majority.
Himadri Speciality Chemical Earnings Call Transcript: Key Takeaways
Himadri delivered massive 58% revenue growth while maintaining steady margins despite high freight costs.
Himadri Speciality Chemical Investor Presentation: Key Takeaways
Himadri reported strong Q2 FY27 performance with revenue at ₹1,691 Cr and PAT at ₹231 Cr, driven by high-value product transitions and expansion into battery materials.
Himadri Speciality Chemical Results Update
Himadri Speciality Chemical reported consolidated H1FY27 revenue of ₹3,123 Cr and PAT of ₹460 Cr, reflecting growth across its specialty chemicals and battery material portfolios.
Himadri Speciality Chemical Q2 FY27 Results: Net Profit ₹231.3 Cr, Up 31.3% YoY
Himadri Speciality Chemical Ltd reported revenue from operations of ₹1,691 Cr (+57.9% YoY) and net profit of ₹231.3 Cr (+31.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹231.3 Cr · +31.3% YoY
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.